Frailty score (FS) was developed due to the unfitness of the aging myeloma patients to guide treatment making decisions. However, very few studies validated it in clinical practice. We therefore retrospectively studied 357 symptomatic MM patients, evaluated the impact of FS and age on outcome and compared these variables to other common prognostic factors. FS was estimated following the geriatric assessment formula, while patients were additionally separated into three age groups, up to 60, between 61 and 74 and 75 years old and above. Both FS and age significantly segregated patients with an adverse outcome (p=0.0007 and p<0.00001 respectively). However, FS was highly predictive of outcome in patients between 61 and 74 years old, while, unexpectedly, common prognostic factors behaved differently in the different age-groups.
